CPT® Code 85730 is used to report a partial thromboplastin time (PTT), also known as activated partial thromboplastin time (aPTT), a laboratory test used to evaluate the intrinsic and common pathways of the blood coagulation system.
PTT testing is commonly used to investigate abnormal bleeding or clotting, evaluate coagulation disorders, and monitor unfractionated heparin therapy. Results are interpreted alongside the patient's clinical history and other coagulation studies.
This code represents the laboratory testing service and does not include separate specimen collection or evaluation and management services.
Key Facts About CPT® 85730
- Service type: Laboratory coagulation test
- Test: Partial thromboplastin time (PTT/aPTT)
- Specimen: Plasma, typically citrated plasma
- Test purpose: Evaluate blood coagulation and clotting abnormalities
- Provider type: Physicians, laboratories, and qualified healthcare professionals
Common clinical indications:
- Evaluation of unexplained bleeding or bruising
- Investigation of abnormal coagulation
- Monitoring unfractionated heparin therapy
- Evaluation of suspected clotting factor deficiencies
- Assessment of certain coagulation disorders
- Preprocedural evaluation when clinically indicated
When to Use CPT® 85730
CPT 85730 is appropriate when:
- A provider orders a partial thromboplastin time (PTT/aPTT)
- The patient is being evaluated for a possible coagulation abnormality
- Monitoring is required for unfractionated heparin therapy
- A coagulation assessment is clinically indicated before a procedure or as part of an ongoing evaluation
Examples:
- Evaluating a patient with unexplained excessive bleeding
- Monitoring a patient receiving unfractionated heparin
- Investigating a prolonged coagulation result
- Assessing a patient with a suspected bleeding or clotting disorder
Documentation Requirements
To support CPT 85730 billing, documentation should include:
- Patient identifiers and date of service
- Clinical indication for PTT testing
- Relevant symptoms, medical history, or diagnosis
- Anticoagulant therapy, when applicable
- Specimen information
- PTT/aPTT result and date reported
- Ordering provider information
When the test is used for anticoagulation monitoring, documentation should identify the relevant therapy and clinical rationale.
Reimbursement and Coding Considerations
- CPT 85730 reports partial thromboplastin time testing
- Diagnosis coding should support the medical necessity of coagulation testing
- PTT/aPTT testing may be ordered alongside other coagulation studies when clinically appropriate
- Coverage and frequency limitations vary by payer and clinical indication
- Specimen collection may be separately reportable when permitted by payer policy
Always verify payer-specific coagulation testing and laboratory billing requirements before submitting claims.
How OptiMantra Supports Coagulation Testing
OptiMantra's integrated EMR and practice management platform helps streamline documentation and billing for CPT 85730.
With OptiMantra, providers can:
- Order coagulation laboratory testing within the patient chart
- Document bleeding, clotting, and anticoagulation-related clinical information
- Link laboratory findings to diagnoses and treatment plans
- Maintain organized laboratory documentation that supports billing compliance and audit preparedness
- Coordinate follow-up testing and patient care within the longitudinal record
By centralizing laboratory workflows, OptiMantra helps practices maintain organized documentation and support efficient patient monitoring.
Try OptiMantra for free here!
Disclaimer: CPT® codes are maintained by the American Medical Association. This guide is for informational purposes only and does not replace official coding guidelines or payer policies.
.png)
